Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nef-specific CD45RA+ CD8+ T cells secreting MIP-1beta but not IFN-gamma are associated with nonprogressive HIV-1 infection.
Dembek CJ, Kutscher S, Heltai S, Allgayer S, Biswas P, Ghezzi S, Vicenzi E, Hoffmann D, Reitmeir P, Tambussi G, Bogner JR, Lusso P, Stellbrink HJ, Santagostino E, Vollbrecht T, Goebel FD, Protzer U, Draenert R, Tinelli M, Poli G, Erfle V, Malnati M, Cosma A. Dembek CJ, et al. Among authors: stellbrink hj. AIDS Res Ther. 2010 Jul 2;7:20. doi: 10.1186/1742-6405-7-20. AIDS Res Ther. 2010. PMID: 20598119 Free PMC article.
Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy.
Erdbeer G, Sabranski M, Sonntag I, Stoehr A, Horst HA, Plettenberg A, Schewe K, Unger S, Stellbrink HJ, Fenske S, Hoffmann C. Erdbeer G, et al. Among authors: stellbrink hj. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19673. doi: 10.7448/IAS.17.4.19673. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397423 Free PMC article.
Intermittent viraemia and immune reconstitution in patients with more than 10-15 years of antiretroviral therapy: baseline values still matter.
Erdbeer G, Sabranski M, Sonntag I, Stoehr A, Horst HA, Plettenberg A, Schewe K, Unger S, Stellbrink HJ, Fenske S, Hoffmann C. Erdbeer G, et al. Among authors: stellbrink hj. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19689. doi: 10.7448/IAS.17.4.19689. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397439 Free PMC article.
Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study.
Stephan C, Spinner CD, Rieke A, Christensen S, Mauss S, Schreiber S, Albuquerque B, Heinzkill M, Ramroth H, Stellbrink HJ. Stephan C, et al. Among authors: stellbrink hj. HIV Med. 2024 Oct 30. doi: 10.1111/hiv.13728. Online ahead of print. HIV Med. 2024. PMID: 39476488
Characterising HIV-Indicator conditions among two nationwide long-term cohorts of people living with HIV in Germany (1999-2023).
Krings A, Kollan C, Schmidt D, Gunsenheimer-Bartmeyer B, Valbert F, Neumann A, Wasem J, Behrens GMN, Bickel M, Boesecke C, Esser S, Dröge P, Ruhnke T, Koppe U; HIV-1 Seroconverter, ClinSurv-HIV study groups. Krings A, et al. Infection. 2024 Oct 30. doi: 10.1007/s15010-024-02419-2. Online ahead of print. Infection. 2024. PMID: 39476279
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Nov 22;79(5):1242-1257. doi: 10.1093/cid/ciae228. Clin Infect Dis. 2024. PMID: 38663013
AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999-2018.
Pantke A, Kollan C, Gunsenheimer-Bartmeyer B, Jensen BO, Stephan C, Degen O, Schürmann D, Kurth T, Bremer V, Koppe U; HIV-1 Seroconverter Cohort and the ClinSurv HIV Cohort. Pantke A, et al. Infection. 2024 Apr;52(2):637-648. doi: 10.1007/s15010-024-02188-y. Epub 2024 Feb 21. Infection. 2024. PMID: 38381307 Free PMC article.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. Among authors: stellbrink hj. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
305 results